Promising results for Nano Covax vaccine in phase 3a of clinical trials

VOV.VN - A local research team working on developing Nano Covax, a homegrown COVID-19 vaccine, have unveiled the promising outcomes of the mid-term phase 3a clinical trials.

According to the preliminary evaluation of the National Ethics Committee in Biomedical Research under the Ministry of Health, the domestically-developed vaccine fully meets all safety and immunogenicity requirements.

Moving forward, researchers must submit additional documents early next week in order for the Ministry to review before releasing the final press release.

The clinical trials of phase 3a involved the participation of 1,004 volunteers in both Hanoi and Long An.

The volunteers received their initial jab from June 8, with the second shot being given after 28 days, with the monitoring period scheduled to end in early June, 2022.

The selection of samples of volunteers participating in phase 3a has been done to ensure gender balance and diversity in age groups, with the youngest participant being 18 years old and the oldest 81.

Furthermore, researchers also allowed volunteers with a history of allergies, chronic heart disease, diabetes, hypertension, cancer, and obesity to participate in the clinical trials.

The results of the phase 3a indicate that all participants recorded very good immunogenicity results, with no serious side effects. In addition, the Nano Covax vaccine had a seroconversion rate of up to 99.2% at the 42nd day.

Moreover, the assessment results of the rate of virus neutralising antibody titers by PRNT50 method for those who have been injected reached 96.5%.

With the Nano Covax vaccine therefore meeting the requirements for immunogenicity, the research team has moved to recommend that phase 3b can be conducted on 12,000 volunteers.

Nano Covax represents the first domestically-developed COVID-19 vaccine and is being produced by Nanogen Pharmaceutical Biotechnology JSC based on recombinant DNA/protein technology.

Add new comment

Related

About 200 people sign up for Nanocovax vaccine trial
About 200 people sign up for Nanocovax vaccine trial

VOV.VN - As many as 200 people have registered to participate in clinical trials for the locally-produced Nanocovax vaccine, with screening underway to select 60 people aged between 18 and 50 for the first phase, said Nguyen Ngo Quang, deputy director of the Department of Science, Technology and Training under the Ministry of Health on December 16.

About 200 people sign up for Nanocovax vaccine trial

About 200 people sign up for Nanocovax vaccine trial

VOV.VN - As many as 200 people have registered to participate in clinical trials for the locally-produced Nanocovax vaccine, with screening underway to select 60 people aged between 18 and 50 for the first phase, said Nguyen Ngo Quang, deputy director of the Department of Science, Technology and Training under the Ministry of Health on December 16.

Vietnam strives for at least one successful homegrown COVID-19 vaccine in 2021
Vietnam strives for at least one successful homegrown COVID-19 vaccine in 2021

Vietnam strives to have at least one successful domestically developed COVID-19 vaccine this year, according to deputy health minister Tran Van Thuan.

Vietnam strives for at least one successful homegrown COVID-19 vaccine in 2021

Vietnam strives for at least one successful homegrown COVID-19 vaccine in 2021

Vietnam strives to have at least one successful domestically developed COVID-19 vaccine this year, according to deputy health minister Tran Van Thuan.

Phase 3 human trials of homegrown Nano Covax vaccine approved
Phase 3 human trials of homegrown Nano Covax vaccine approved

VOV.VN - Deputy Minister of Health Tran Van Thuan has signed a decision to approve the third phase of human trials for the locally-produced Nano Covax vaccine against the COVID-19.

Phase 3 human trials of homegrown Nano Covax vaccine approved

Phase 3 human trials of homegrown Nano Covax vaccine approved

VOV.VN - Deputy Minister of Health Tran Van Thuan has signed a decision to approve the third phase of human trials for the locally-produced Nano Covax vaccine against the COVID-19.